Gray

Gray is a prescription oral medication that contains the active ingredient Levofloxacin Hemihydrate. It belongs to the fluoroquinolone class of antibiotics and is marketed in the European Union. The product is formulated for systemic antibacterial therapy, targeting a range of bacterial infections. Gray is supplied without a specified strength or dosage form in this description, and it requires a healthcare professional’s prescription.

Gray is indicated for the treatment of several bacterial infections where levofloxacin is appropriate. Clinical use is guided by susceptibility testing and local guidelines.

- Community‑acquired and hospital‑acquired respiratory tract infections, including pneumonia and bronchitis - Uncomplicated urinary tract infections and acute pyelonephritis - Skin and soft‑tissue infections such as cellulitis and wound infections - Acute bacterial sinusitis and chronic prostatitis - Certain infections caused by susceptible Gram‑negative and Gram‑positive organisms

Levofloxacin, the active component of Gray, can cause a range of adverse reactions. They are typically categorized by frequency and severity.

Common: - Nausea, vomiting, or abdominal discomfort - Diarrhea or loose stools - Headache or dizziness - Mild skin rash or itching - Photosensitivity (increased sensitivity to sunlight)

Serious: - Tendon rupture or tendonitis, especially in the Achilles tendon - Peripheral neuropathy (numbness, tingling, or weakness) - QT interval prolongation leading to cardiac arrhythmias - Severe hypersensitivity reactions such as Stevens‑Johnson syndrome - Clostridioides difficile‑associated colitis

Before prescribing Gray, clinicians should evaluate patient‑specific factors and potential risks. Key safety considerations include:

- Known hypersensitivity to levofloxacin, other fluoroquinolones, or any formulation components - History of tendon disorders, especially in patients over 60 years or those on corticosteroids - Pre‑existing cardiac conditions that may predispose to QT prolongation - Renal impairment, which may require dose adjustment - Pregnancy and lactation status, as safety data are limited - Concomitant use of drugs that may lower seizure threshold

Levofloxacin can interact with other medications, affecting efficacy or safety. Interaction management is essential.

Avoid: - Antacids, sucralfate, or multivitamins containing magnesium, aluminum, calcium, or iron taken within 2 hours of the dose (reduces absorption) - Non‑steroidal anti‑inflammatory drugs (NSAIDs) that increase seizure risk - Drugs that prolong the QT interval, such as certain antiarrhythmics or macrolide antibiotics

Use with caution: - Warfarin (may enhance anticoagulant effect; monitor INR) - Theophylline (potential for increased plasma concentrations) - Corticosteroids (higher risk of tendon injury) - Diabetes medications (possible alteration of glucose control) - Other antibiotics that may compete for the same bacterial targets